Eli Lilly and Company (LLY) compared with its closest peers (MRK, GILD, JNJ, ABBV, PFE): P/E 38.6 vs industry 15.8. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Merck & Company, Inc. Common Stock (new), Gilead Sciences, Johnson & Johnson, AbbVie, Pfizer, Bristol-Myers Squibb, Abbott Laboratories, Viatris, Organon and Zoetis share Eli Lilly and's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Merck & Company, Inc. Common Stock (new) (MRK) | $362.47B | 114.2 |
| Gilead Sciences, Inc. (GILD) | $186.50B | 18.1 |
| Johnson & Johnson (JNJ) | $658.63B | 31.3 |
| AbbVie Inc. (ABBV) | $466.32B | 73.9 |
| Pfizer, Inc. (PFE) | $157.46B | 36.3 |
| Bristol-Myers Squibb Company (BMY) | $129.09B | 13.9 |
| Abbott Laboratories (ABT) | $177.43B | 28.3 |
| Viatris Inc. (VTRS) | $19.72B | 239.5 |
| Organon & Co. (OGN) | $3.70B | 17.7 |
| Zoetis Inc. (ZTS) | $29.95B | 11.5 |
| Stock P/E | 38.6 |
| Sector P/E (Healthcare) | 20.9 |
| Industry P/E (Pharmaceutical Products) | 15.8 |
| vs Sector | 84.5% |
| vs Industry | 143.6% |
LLY overview · LLY earnings · LLY financials · LLY KPIs · LLY documents · LLY ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.